Psycho-oncology

AMERICAN GROUP PSYCHOTHERAPY ASSOCIATION ANNOUNCES LAUNCH OF EVIDENCE-BASED GROUP TREATMENT WEBSITE

Retrieved on: 
Monday, February 12, 2024
Private practice, Mental health, Doctor of Philosophy, American Psychological Association, American Group Psychotherapy Association, Psycho-oncology, CGP, Mental, DSM-IV codes, Society, Convention center, American Psychologist, Depression, Group Therapy, Social anxiety, Meta-analysis, Workforce, Brigham Young University, AGPA

NEW YORK, Feb. 12, 2024 /PRNewswire/ -- The American Group Psychotherapy Association announced the launch of an Evidence-Based Group Treatment Website at https://evidencebasedgrouptherapy.org/.

Key Points: 
  • Group Therapy Will be Key for Mental Health Treatment Access and New Website Will Serve as a Resource for Effective, Disorder Specific Group Treatments Supported by Evidence
    This website has been developed by an international team of renowned mental health professionals and supported by the American Psychological Association's Society of Group Psychology and Group Psychotherapy (Division 49), the American Group Psychotherapy Association (AGPA) with funding provided by the Group Foundation for Advancing Mental Health, and the German Health Ministry.
  • The use of group can address this issue, and this website can serve as a resource for treatment information and the basis of trainings to increase practitioner's comfort in providing group therapy.
  • Moreover, agencies who provide the highest percentage of group treatment in the US could extend their group treatment offerings by employing evidence-based protocols found on the website for the most common psychiatric disorders.
  • This website is a valuable resource in providing access to information on the most effective treatments for common mental health challenges."

Recognizing and Celebrating Outstanding Contributions to the Canadian Cancer Research Community

Retrieved on: 
Monday, November 6, 2023
Women of Outstanding Achievement Photographic Exhibition, FRSC, ISCB Senior Scientist Award, Order of Ontario, FCAN, Medical research, Myeloma Canada, Molecular biology, Multiple myeloma, FRS, Genetics, Jewish General Hospital, Psycho-oncology, RN, Conference, Organization, Federation, Doctor of Philosophy, FRCPC, Doctor of Science, University of Hong Kong, Research, Toronto Metropolitan University, Patient, Senior, McGill University, Princess Margaret Cancer Centre, Professor, University of Toronto, Immune system, Canadian Partnership Against Cancer, University, OC, FCAHS, Palliative care, Distinguished Service to Music Medal, CCRA, Toronto, Breast cancer, University Health Network, University of Manitoba, Ovarian Cancer Research Alliance, Pharmaceutical industry, Nursing, Management, MD, Pharmacology, Cancer

TORONTO, Nov. 6, 2023 /CNW/ - Today, the Canadian Cancer Research Alliance (CCRA) announces the recipients of its biennial awards, recognizing significant contributions to cancer research in Canada.

Key Points: 
  • TORONTO, Nov. 6, 2023 /CNW/ - Today, the Canadian Cancer Research Alliance (CCRA) announces the recipients of its biennial awards, recognizing significant contributions to cancer research in Canada.
  • Awardees will be honoured at the Canadian Cancer Research Conference, which is taking place in Halifax from November 12 to 14.
  • Initiated in 2011, the CCRA Awards acknowledge and celebrate the contributions of individuals who have had a remarkable impact on cancer research and the cancer research community, as well as those who have shown exceptional leadership in patient involvement in cancer research.
  • The Canadian Cancer Research Alliance (CCRA) is an alliance of organizations that collectively fund most of the cancer research conducted in Canada – research that will lead to better ways to prevent, diagnose, and treat cancer, and improve patient and survivor outcomes.

Forge Health Welcomes Guy Maytal, MD as Chief of Integrated Care

Retrieved on: 
Tuesday, June 27, 2023
General Health, Mental Health, Health, Practice Management, Oncology, MGH, Integrated care, Internal medicine, Psycho-oncology, Cancer, Multimedia, Harvard Medical School, Forge, Medical director, MD, Patient, Psychosomatic medicine, Psychiatry, Weill Cornell Medicine, Knowledge, Diagnosis, Government, Hospital, Massachusetts General Hospital, Mental health, Clinical, Accountable care organization, Nursing

Forge Health (“Forge” or the “Company”), a leading provider of value-based mental health and substance use care, today announced Guy Maytal, MD has joined the organization as Chief of Integrated Care and Head of Psycho-oncology.

Key Points: 
  • Forge Health (“Forge” or the “Company”), a leading provider of value-based mental health and substance use care, today announced Guy Maytal, MD has joined the organization as Chief of Integrated Care and Head of Psycho-oncology.
  • View the full release here: https://www.businesswire.com/news/home/20230627150161/en/
    In this role, Dr. Maytal will oversee the next generation of the Forge Health integrated care model, providing the highest quality mental health and substance use care to individuals with coexisting health conditions in close collaboration with their other medical providers.
  • “At Forge Health we believe that close collaboration between behavioral health professionals and physical medicine providers is critical to improving a patient’s overall well-being,” said Eric Frieman, co-founder and CEO of Forge Health.
  • “I’m thrilled to join Forge Health during this critical time of transformation in the healthcare industry," said Dr. Maytal.

Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer

Retrieved on: 
Wednesday, February 1, 2023
Biotechnology, Hospitals, Health, Pharmaceutical, Oncology, Organization, Woman, Health equity, General counsel, Native Americans, Transport, Breast cancer, Science, Psycho-oncology, Gilead Sciences, Risk, Black, Triple-negative breast cancer, LGBTQIA, Corporate Affairs, Birth control, Jews

Gilead Sciences, Inc. (Nasdaq: GILD) awarded $7.6 million in grant funding to 24 U.S.-based, community organizations through the newly created Toward Health Equity (THE) Oncology Grant™.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) awarded $7.6 million in grant funding to 24 U.S.-based, community organizations through the newly created Toward Health Equity (THE) Oncology Grant™.
  • “Gilead is committed to advancing health equity and supporting these vital patient advocacy organizations working to close gaps in breast cancer care,” said Deborah H. Telman, Executive Vice President, Corporate Affairs and General Counsel, Gilead Sciences.
  • “We believe our Toward Health Equity Oncology Grant awards contribute important new understanding to advance and care for anyone living with breast cancer.
  • THE Oncology Grant builds on Gilead’s 2022 program , which provided $5.7 million in grants to 21 U.S. organizations for programs working to advance health equity for Black people impacted by triple-negative breast cancer.

BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care

Retrieved on: 
Tuesday, November 15, 2022
Mental Health, Research, Clinical Trials, Health Technology, Biotechnology, Health, Pharmaceutical, Science, Oncology, Marketing, City, Behavioural sciences, Cancer, CLL, Safety, Disease, Hematology, Risk, Memorial Sloan Kettering Cancer Center, Social work, University of Houston–Downtown, Cancer Support Community, News, Meta-analysis, Doctor of Philosophy, SSE, Survivor, American Society of Hematology, Research, Depression, Intellectual property, University, COVID-19, CSC, We Need to Talk about Dad, Prevalence, Psychiatry, Caregiver, Therapy, LCSW, Master of Education, Education, Psycho-oncology, Society, Public policy, Mental health, Organization, Associate, Patient, Pharmaceutical industry, Residential care, Medicine, BeiGene

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the launch of a new program, Talk About It: Cancer and Mental Health, designed to elevate the important intersection of mental health and cancer care to help improve health outcomes for cancer patients.

Key Points: 
  • BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the launch of a new program, Talk About It: Cancer and Mental Health, designed to elevate the important intersection of mental health and cancer care to help improve health outcomes for cancer patients.
  • Aimed at patients and caregivers, healthcare professionals and policymakers, Talk About It draws attention to mental health care as a critical component of quality cancer care.
  • By bringing visibility to the importance of mental health and cancer care, this campaign will take an important step toward improving health outcomes for cancer patients by looking at the patient holistically when it comes to treatment."
  • CSC is a global nonprofit organization that provides free emotional support, navigation and resources to cancer patients and their loved ones.

Numinus completes acquisition of Novamind and announces executive appointments

Retrieved on: 
Saturday, June 11, 2022
Mission statement, Psychotherapy, Time, Company, Lists of diseases, Trauma, Pain, Toronto Stock Exchange, Medical director, Certification, Psycho-oncology, Psychedelic therapy, University, RSU, Cancer, CSE, Canadian Securities Exchange, Depression, Legislation, Transaction, CEO, Partnership, Center, Par value, Multidisciplinary Association for Psychedelic Studies, MD, Psychiatry, MAPS, Indian stock exchange, SEDAR, Experiential learning, Anxiety, Supreme Court of British Columbia, Patient, Alternative, Acquisition, TSX, Ketamine, California Institute for Quantitative Biosciences, Research, News, FDA, Growth, Clinic, Brigham Young University, Risk, Nursing care plan, Cost-exchange ratio, Opioid use disorder, Medicine, Pharmaceutical industry, Security (finance), Esketamine, List of cosmic entities in Marvel Comics, BC

This acquisition significantly grows Numinus' client service offerings, geographic reach, and revenues.

Key Points: 
  • This acquisition significantly grows Numinus' client service offerings, geographic reach, and revenues.
  • Numinus is also pleased to announce the appointments of Dr. Reid Robison (MD) as Chief Clinical Officer and Dr. Paul Thielking (MD) as Chief Science Officer, who both join the Company from Novamind.
  • As approved by shareholders on June 8, 2022, Numinus has issued 43,474,659 common shares to the former shareholders and RSU holders of Novamind, as consideration for the acquisition representing 0.84 of one (the "Exchange Ratio") Numinus common share per each Novamind share and Novamind restricted share unit (RSU).
  • Given securities processing times, these Numinus shares should settle in Novamind investor accounts by June 16, 2022.

Cancer Registry Software Market size worth $ 123.67 Million, Globally, by 2028 at 11.4% CAGR: Verified Market Research®

Retrieved on: 
Monday, May 16, 2022
Population, Marital status, Incidence, COC, Patient, Solution, SEER, Psycho-oncology, USD, Database, Cancer, Software, Telehealth, Time, Commercial, Health information exchange, Standalone software, Integrated software, Research, Geography, Adoption, McKesson Corporation, AJCC, CAGR, Market research, Prevalence, PUB, Mobile phone

JERSEY CITY, N.J., May 16, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Cancer Registry Software Market" By Type (Integrated Software, Standalone Software), By Database Type (Public Databases, Commercial Databases), By Functionality (Product Outcome Evaluation, Patient Care Management), By End User (Research Centre, Private Payers), and By Geography. According to Verified Market Research, the Global Cancer Registry Software Market size was valued at USD 52.12 Million in 2020 and is projected to reach USD 123.67 Million by 2028, growing at a CAGR of 11.4% from 2021 to 2028.

Key Points: 
  • JERSEY CITY, N.J., May 16, 2022 /PRNewswire/ -- Verified Market Research recently published a report, " Cancer Registry Software Market " By Type (Integrated Software, Standalone Software), By Database Type (Public Databases, Commercial Databases), By Functionality (Product Outcome Evaluation, Patient Care Management), By End User (Research Centre, Private Payers), and By Geography.
  • According to Verified Market Research, the Global Cancer Registry Software Market size was valued at USD 52.12 Million in 2020 and is projected to reach USD 123.67 Million by 2028, growing at a CAGR of 11.4% from 2021 to 2028.
  • With the rising incidence of cancer and favorable government, the market for cancer registry software is growing.
  • Verified Market Research has segmented the Global Cancer Registry Software Market On the basis of Type, Database Type, Functionality, End User, and Geography.

Cancer Registry Software Market size worth $ 123.67 Million, Globally, by 2028 at 11.4% CAGR: Verified Market Research®

Retrieved on: 
Monday, May 16, 2022
Population, Marital status, Incidence, COC, Patient, Solution, SEER, Psycho-oncology, USD, Database, Cancer, Software, Telehealth, Time, Commercial, Health information exchange, Standalone software, Integrated software, Research, Geography, Adoption, McKesson Corporation, AJCC, CAGR, Market research, Prevalence, PUB, Mobile phone

JERSEY CITY, N.J., May 16, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Cancer Registry Software Market" By Type (Integrated Software, Standalone Software), By Database Type (Public Databases, Commercial Databases), By Functionality (Product Outcome Evaluation, Patient Care Management), By End User (Research Centre, Private Payers), and By Geography. According to Verified Market Research, the Global Cancer Registry Software Market size was valued at USD 52.12 Million in 2020 and is projected to reach USD 123.67 Million by 2028, growing at a CAGR of 11.4% from 2021 to 2028.

Key Points: 
  • JERSEY CITY, N.J., May 16, 2022 /PRNewswire/ -- Verified Market Research recently published a report, " Cancer Registry Software Market " By Type (Integrated Software, Standalone Software), By Database Type (Public Databases, Commercial Databases), By Functionality (Product Outcome Evaluation, Patient Care Management), By End User (Research Centre, Private Payers), and By Geography.
  • According to Verified Market Research, the Global Cancer Registry Software Market size was valued at USD 52.12 Million in 2020 and is projected to reach USD 123.67 Million by 2028, growing at a CAGR of 11.4% from 2021 to 2028.
  • With the rising incidence of cancer and favorable government, the market for cancer registry software is growing.
  • Verified Market Research has segmented the Global Cancer Registry Software Market On the basis of Type, Database Type, Functionality, End User, and Geography.

Rocket VR Announces New Study Exploring The Impact of Virtual Reality Therapeutics on Chronic Pain in Cancer Patients

Retrieved on: 
Thursday, May 5, 2022
Linda, Sleep, Cumming School of Medicine, CRP, University, Brain, Pain, VR, Mindfulness, Cancer, Health, Fatigue, Research, Prevalence, Patient, Mind, Partnership, Environment, Therapy, University of Calgary, Depressive, Conditional sentence, Virtual reality, Rocket, Adult, Quality of life, Psycho-oncology, Survivor, Chronic pain, Mental health, CEO, Entrepreneurship, Disease, Medical imaging, Pharmaceutical industry, Medicine, Medicine

BOSTON, May 5, 2022 /PRNewswire/ -- Rocket VR Health, a digital therapeutics company developing immersive therapy programs, is pleased to announce a new study in partnership with Dr. Linda Carlson, Enbridge Research Chair in Psychosocial Oncology at the University of Calgary Cumming School of Medicine. The first-of-its-kind study will assess the feasibility of a virtual reality guided mindfulness (VRGM) intervention program in adult cancer patients with chronic cancer-related pain (CRP).

Key Points: 
  • The first-of-its-kind study will assess the feasibility of a virtual reality guided mindfulness (VRGM) intervention program in adult cancer patients with chronic cancer-related pain (CRP).
  • "Our team at Rocket VR believes virtual reality therapies have the potential to change the way cancer care is delivered," said Sid Desai, CEO and Co-Founder of Rocket VR Health.
  • "Through the 'Virtual Mind' study, Rocket VR Health is helping us gauge the potential of virtual reality technologies to achieve meaningful clinical improvements for cancer patients."
  • Rocket VR Health is developing immersive prescription digital therapeutics to address unmet mental health needs in cancer patients and survivors.

The Lung Cancer Registry Launches New International Survey Focused on Experiences and Mental Health of Caregivers

Retrieved on: 
Tuesday, March 1, 2022
University of Colorado School of Medicine, Risk, Depression, Partnership, Human, Psycho-oncology, American Lung Association, Center, Registry, Diagnosis, Awareness, Science, Veni, vidi, vici, University, Novartis, Survivor, Disease, Mental health, International Association, Multimedia, View, Caregiver, Kent, Lung cancer, Cancer, Anxiety, SAN, Patient, Quality of life, Survival, Strathcona County, Large-cell lung carcinoma, Research, Shoe, Lung, Oncology, Doctor of Philosophy, Residential care, Medicine, Medicine

Although not much is known about the co-survivorship experience of caregivers and patients living with lung cancer, as many as 50% of caregivers for patients with cancer experience significant anxiety or depression.1,2

Key Points: 
  • Although not much is known about the co-survivorship experience of caregivers and patients living with lung cancer, as many as 50% of caregivers for patients with cancer experience significant anxiety or depression.1,2
    GO2 Foundation's Lung Cancer Registry has staff researchers ready to analyze survey responses as they are submitted.
  • GO2 Foundation's Lung Cancer Registry has staff researchers ready to analyze survey responses as they are submitted, allowing for enhanced understanding of co-survivorship experiences.
  • The Lung Cancer Registry is a community for people with all forms of lung cancer.
  • Founded in 2016, the Lung Cancer Registry is a core program of the GO2 Foundation for Lung Cancer.